Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 35496-35497 [2010-15016]
Download as PDF
<![CDATA[
35496
Federal Register / Vol. 75, No. 119 / Tuesday, June 22, 2010 / Notices
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 15, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams, Conference Management
Staff, at 301–796–5966, at least 7 days
in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 15, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–15020 Filed 6–21–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Cardiovascular and Renal Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
srobinson on DSKHWCL6B1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Cardiovascular
and Renal Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on July 29, 2010, from 8 a.m. to 5
p.m.
Location: The Marriott Inn and
Conference Center, University of
Maryland University College, 3501
VerDate Mar<15>2010
16:17 Jun 21, 2010
Jkt 220001
University Blvd. East, Adelphi, MD. The
conference center telephone number is
301–985–7300.
Contact Person: Elaine Ferguson, c/o
Christine Shipe, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, rm. 2419,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8532, e-mail:
elaine.ferguson@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512533. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On July 29, 2010, the
committee will discuss Revatio
(sildenafil) for the treatment of pediatric
pulmonary arterial hypertension (PAH)
and whether to amend the clinical trials
section of the written request, issued by
FDA to Pfizer, to include assessment of
a hemodynamic endpoint. An area of
particular interest will be what the
appropriate study endpoint should be in
patients with PAH unable to perform
exercise testing. The discussion will
help the agency determine what studies
to request for products intended to treat
pediatric PAH.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before July 14, 2010. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before July 6, 2010. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 7, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Elaine
Ferguson at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: June 15, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–15019 Filed 6–21–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH or Advisory
Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting for the
aforementioned committee:
Time and Date: 11 a.m.–3 p.m., July
14, 2010.
E:\FR\FM\22JNN1.SGM
22JNN1
srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 119 / Tuesday, June 22, 2010 / Notices
Place: Audio Conference Call via FTS
Conferencing. The USA toll-free, dial in
number is 1–866–659–0537 and the pass
code is 9933701.
Status: Open to the public, but
without a public comment period.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines,
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to the CDC.
NIOSH implements this responsibility
for CDC. The charter was issued on
August 3, 2001, renewed at appropriate
intervals, most recently, August 3, 2009,
and will expire on August 3, 2011.
Purpose: This Advisory Board is
charged with: (a) Providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters to be Discussed: The agenda
for the conference call includes: SEC
Petitions for Blockson Chemical,
General Electric Company (Ohio), and
Chapman Valve; NIOSH 10-Year Review
of its Division of Compensation
Analysis and Support (DCAS) Program;
Review of Public Comments to the
Advisory Board during February
Meeting; Advisory Board Subcommittee
and Work Group Updates; and, DCAS
VerDate Mar<15>2010
16:17 Jun 21, 2010
Jkt 220001
SEC Petition Evaluations Update for the
August 2010 Advisory Board Meeting.
The agenda is subject to change as
priorities dictate.
Because there is not a public
comment period, written comments may
be submitted. Any written comments
received will be included in the official
record of the meeting and should be
submitted to the contact person below
in advance of the meeting.
FOR FURTHER INFORMATION CONTACT:
Contact Person For More Information:
Theodore M. Katz, M.P.A., Executive
Secretary, NIOSH, CDC, 1600 Clifton
Rd., NE., Mailstop: E–20, Atlanta, GA
30333, Telephone (513) 533–6800, Toll
Free 1–800–CDC–INFO, e-mail
ocas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: June 15, 2010.
Elaine L. Baker, M.P.H.,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–15016 Filed 6–21–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Updated Guidance: Prevention
Strategies for Seasonal Influenza in
Healthcare Settings
AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
SUMMARY: The Centers for Disease
Control and Prevention (CDC), located
in the Department of Health and Human
Services (HHS), seeks public comment
on proposed new guidance which will
update and replace previous seasonal
influenza guidance and the Interim
Guidance on Infection Control Measures
for 2009 H1N1 Influenza in Healthcare
Settings.
The updated guidance emphasizes a
prevention strategy to be applied across
the entire spectrum of healthcare
settings, including hospitals, nursing
homes, physicians’ offices, urgent-care
centers, and home health care, but is not
intended to apply to settings whose
primary purpose is not health care. It
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
35497
focuses on the importance of
vaccination, steps to minimize the
potential for exposure such as
respiratory hygiene, management of ill
healthcare workers, droplet and aerosolgenerating procedure precautions,
surveillance, and environmental and
engineering controls.
CDC will consider the comments
received and intends to publish the final
guidance prior to the 2010–2011
influenza season.
DATES: Written comments must be
received on or before July 22, 2010.
Comments received after July 22, 2010
will be considered to the extent
possible.
ADDRESSES: You may submit written
comments to the following address:
Influenza Coordination Unit, Centers for
Disease Control and Prevention, U.S.
Department of Health and Human
Services, Attn: Prevention Strategies for
Seasonal Influenza in Healthcare
Settings, 1600 Clifton Road, NE., MS A–
20, Atlanta, GA 30333.
You may also submit written
comments via e-mail to:
ICUpubliccomments@cdc.gov.
FOR FURTHER INFORMATION CONTACT: Julie
Edelson, Influenza Coordination Unit,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE., MS
A–20, Atlanta, GA 30333; telephone
404–639–2293.
SUPPLEMENTARY INFORMATION: In 2009,
CDC posted on its Web site Interim
Guidance on Infection Control Measures
for 2009 H1N1 Influenza in Healthcare
Settings, Including Protection of
Healthcare Personnel. At the time it was
posted, uncertainties existed regarding
the novel H1N1 influenza strain, and
the vaccine was not yet widely
available. As stated in that document,
CDC planned to update the guidance
when new information became
available. Since then, circumstances
have changed. A safe and effective
vaccine has become widely available,
and is being included in the 2010–2011
seasonal influenza vaccine. Further, we
now have information about the number
of cases of disease, hospitalizations, and
deaths caused by 2009 H1N1, which can
be compared to historical seasonal
influenza data. At this point, an update
of the guidance to address current
circumstances is warranted.
Additionally, recommendations for
prevention of seasonal influenza in
healthcare facilities are currently found
throughout the influenza section of the
CDC Web site. By posting this proposed
guidance, CDC will consolidate a range
of evidence-based strategies into a
comprehensive, easily-accessible
document.
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 75, Number 119 (Tuesday, June 22, 2010)]
[Notices]
[Pages 35496-35497]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-15016]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Board on Radiation and Worker Health (ABRWH or Advisory
Board), National Institute for Occupational Safety and Health (NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting for the
aforementioned committee:
Time and Date: 11 a.m.-3 p.m., July 14, 2010.
[[Page 35497]]
Place: Audio Conference Call via FTS Conferencing. The USA toll-
free, dial in number is 1-866-659-0537 and the pass code is 9933701.
Status: Open to the public, but without a public comment period.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines, which have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule; advice on methods of dose reconstruction, which have
also been promulgated by HHS as a final rule; advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program; and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC).
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate intervals, most recently, August 3, 2009, and
will expire on August 3, 2011.
Purpose: This Advisory Board is charged with: (a) Providing advice
to the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advising the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Matters to be Discussed: The agenda for the conference call
includes: SEC Petitions for Blockson Chemical, General Electric Company
(Ohio), and Chapman Valve; NIOSH 10-Year Review of its Division of
Compensation Analysis and Support (DCAS) Program; Review of Public
Comments to the Advisory Board during February Meeting; Advisory Board
Subcommittee and Work Group Updates; and, DCAS SEC Petition Evaluations
Update for the August 2010 Advisory Board Meeting.
The agenda is subject to change as priorities dictate.
Because there is not a public comment period, written comments may
be submitted. Any written comments received will be included in the
official record of the meeting and should be submitted to the contact
person below in advance of the meeting.
FOR FURTHER INFORMATION CONTACT: Contact Person For More Information:
Theodore M. Katz, M.P.A., Executive Secretary, NIOSH, CDC, 1600 Clifton
Rd., NE., Mailstop: E-20, Atlanta, GA 30333, Telephone (513) 533-6800,
Toll Free 1-800-CDC-INFO, e-mail ocas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: June 15, 2010.
Elaine L. Baker, M.P.H.,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2010-15016 Filed 6-21-10; 8:45 am]
BILLING CODE 4163-18-P
